Mankind Pharma Q2 Profit Jumps 39% to Rs 712 Crore
Mankind Pharma reported net profit of Rs 712 crore for the September quarter, up 39% year on year. Its board also approved the merger of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell.
Company’s board approves the merger of two wholly owned subsidiaries, Prolijune Lifesciences and Pavi Buildwell, with Mankind PharmaMankind Pharma reported a 39.2 per cent year-on-year increase in net profit to Rs 712 crore for the September quarter, supported by stronger revenue growth and an impr…